Bragar Eagel & Squire, P.C. has announced the filing of class action lawsuits against PayPal Holdings, Inc. and REGENXBIO Inc., alleging material misrepresentations to investors. The dual litigation efforts target significant corporate disclosures that investors claim failed to reflect underlying operational challenges at both companies.
PayPal faces allegations that the company provided revenue projections and growth targets that subsequently proved unachievable. The lawsuit was precipitated by a sharp market reaction following the company's fourth-quarter 2025 results, which disappointed investors and contributed to a 20% decline in the company's stock price. The disappointing performance also coincided with a transition in the company's chief executive officer position. REGENXBIO faces separate allegations that the biopharmaceutical company concealed safety concerns related to its RGX-111 gene therapy candidate. The FDA issued a clinical hold on the therapy program following identification of a tumor in a trial participant, prompting a 17.8% stock decline after the disclosure.
The law firm is inviting investors who believe they sustained losses in either company to contact the firm regarding potential participation in the class actions. These suits represent ongoing investor scrutiny of corporate disclosure practices and regulatory compliance in both the financial services and biopharmaceutical sectors.